Replimune REPL
NASDAQ REPL
$23.28 +1.02 (+4.58%)
At close: Nov 10, 2026 · 4:00 PM EST

Replimune (REPL) Preferred Stock Liabilities (2018)

Updated

Replimune's Preferred Stock Liabilities was $86.36 million in fiscal Q1 2019 (quarter ended Jun 30, 2018), unchanged from the prior quarter.

Analysis

Replimune (REPL) Preferred Stock Liabilities (2018) Analysis & Trends

  • In earlier fiscal years, Preferred Stock Liabilities was $31.61 million in FY2017.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Replimune 2.40 Bn 1.35 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 86.36 Mn
Mar 31, 2018 86.36 Mn
API Access

Replimune Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=REPL&period=max&api_key=YOUR_API_KEY